Journal of Neuro-Oncology

, Volume 75, Issue 1, pp 71–83

Leukemic and lymphomatous meningitis: incidence, prognosis and treatment

  • Marc C. Chamberlain
  • Craig Nolan
  • Lauren E. Abrey
Article

Summary

Neoplastic meningitis (NM) is a common problem in neuro-oncology occurring in approximately 5% of all patients with cancer. Notwithstanding frequent focal signs and symptoms in NM, NM is a disease affecting the entire neuraxis and therefore staging and treatment need encompass all cerebrospinal fluid (CSF) compartments. Central nervous system (CNS) staging of NM includes contrast enhanced cranial computerized tomography (CE-CT) or magnetic resonance imaging (MR-Gd), contrast enhanced spine magnetic resonance imaging (MR-S) or computerized tomographic myelography (CT-M) and radionuclide CSF flow study (FS). Treatment of NM involves involved-field radiotherapy of bulky or symptomatic disease sites and intra-CSF drug therapy. The inclusion of concomitant systemic therapy may benefit patients with NM and may obviate the need for intra-CSF chemotherapy. At present, intra-CSF drug therapy is confined to three chemotherapeutic agents (i.e. methotrexate, cytosine arabinoside and thio-TEPA) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. Although treatment of NM is palliative with an expected median patient survival of 4 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM. In patients with leukemia or lymphoma, prophylaxis of the CNS is used (utilizing a combination of high-dose systemic chemotherapy and intra-CSF chemotherapy) for patients at high risk as defined by specific tumor-related laboratory markers. Using such a risk-stratified approach, the late occurrence of CNS relapse has decreased dramatically attesting to the value of CNS prophylaxis.

Keywords

leukemic meningitis lymphomatous meningitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DeAngelis, LM 1998Current diagnosis and treatment of leptomeningeal metastasisJ Neuro Oncol38245252CrossRefGoogle Scholar
  2. 2.
    Kaplan, JG, DeSouza, TG, Farkash, A, Shafran, B, Pack, D, Rehman, F, Fuks, J, Portenoy, R 1990Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemiasJ Neuro Oncol9225229Google Scholar
  3. 3.
    Oostenbrugge, RJ, Twijnstra, A 1999Presenting features and value of diagnostic procedures in leptomeningeal metastasesNeurology53382385PubMedGoogle Scholar
  4. 4.
    Surapaneni UR, Cortes JE, Thomas D et al.: Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia. Cancer 94(3): 2002.Google Scholar
  5. 5.
    Haioun, C, Besson, C, Lepage, E,  et al. 2000Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patientsAnn Oncol11685690CrossRefPubMedGoogle Scholar
  6. 6.
    Hollender, A, Kvaloy, S, Nome, O,  et al. 2002Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk modelAnn Oncol1310991107CrossRefPubMedGoogle Scholar
  7. 7.
    Kantarijian, HM, O'Brien, S, Swmith, TL.,  et al. 2000Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult a cute lymphocytic leukemiaJ Clin Oncol18547561PubMedGoogle Scholar
  8. 8.
    Kantarjian, HM, Walters, RS, Smith, TL,  et al. 1988Identification of risk groups for development of central nervous system leukemia in adults with acutelymphocytic leukemiaBlood7217841789PubMedGoogle Scholar
  9. 9.
    Bishop, PC, Wilson, WH, Pearson, D, Janik, J, Jaffe, ES, Elwood, PC 1999CNS involvement in primary mediastinal large B-cell lymphomaJ Clin Oncol1724792485PubMedGoogle Scholar
  10. 10.
    Recht, L, Straus, DJ, Cirrincione, C, Thaler, HT, Posner, JB 1988Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxisAm J Med84425435CrossRefPubMedGoogle Scholar
  11. 11.
    Bollen, EL, Brouwer, RE, Hamers, S, Hermans, J, Kluin, M, Sankatsing, SU, A-Tjak, RV, Charvat, MV, Kluin-Nelemans, JC 1997Central nervous system relapse in non-Hodgkin's lymphoma: A single-center study of 532 patientsArch Neurol54854859PubMedGoogle Scholar
  12. 12.
    Ersboll, J, Schultz, HB, Thomsen, BL, Keiding, N, Nissen, NI 1985 Meningeal involvement in non-Hodgkin's lymphoma : symptoms, incidence, risk factors and treatmentScand J Haematol35487496PubMedGoogle Scholar
  13. 13.
    Litam, JP, Cabanillas, F, Smith, TL, Bodey, GP, Freireich, EJ. 1979Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxisBlood5412491257PubMedGoogle Scholar
  14. 14.
    Liang, R, Chiu, E, Loke, SL 1990Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factorsHematol Oncol8141145PubMedGoogle Scholar
  15. 15.
    Besien, K, Ha, CS, Murphy, S, McLaughlin, P, Rodriguez, A, Amin, K, Forman, A, Romaguera, J, Hagemeister, F, Younes, A, Bachier, C, Sarris, A, Sobocinski, KS, Cox, JD, Cabanillas, F 1998Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphomaBlood9111781184PubMedGoogle Scholar
  16. 16.
    Chamberlain, MC, Kormanik, PA 1997Non-AIDS related lymphomatous meningitis: Combined modality therapyNeurology4917281731PubMedGoogle Scholar
  17. 17.
    Levitt, LJ, Dawson, DM, Rosenthal, DS,  et al. 1980CNS involvement in the non-Hodgkin's lymphomaCancer45545552PubMedGoogle Scholar
  18. 18.
    O'Neill BP.: Neurologic Complications of Hodgkin's disease and the non-Hodgkin's lymphomas: Cancer Neurol Clin Prac 371–384.Google Scholar
  19. 19.
    Reiche, HH 2003Leukemia. In Cancer Neurology in Clinical PracticeHumana Press Inc.Totowa, New Jersey355369Google Scholar
  20. 20.
    Recht L, Mrugala M. Neurologic complications of hematologic neoplasms. Neurologic Clinics, W.B. Saunders Company. 2003, Vol. 21, No. 1. pp 87–105.Google Scholar
  21. 21.
    Wolk, RW, Masse, SR, Conklin, R, Freireich, EJ. 1974The incidence of central nervous system leukemia in adults with acute leukemiaCancer33863PubMedGoogle Scholar
  22. 22.
    Stewart, DJ, Keating, MJ, McCredie, KB,  et al. 1981Natural history of central nervous system acute leukemia in adultsCancer47184196PubMedGoogle Scholar
  23. 23.
    Meyer, RJ, Ferreira, PP, Cuttner, J.,  et al. 1980Central nervous system involvement at presentation in acute granulocytic leukemia. a prospective cytocentrifuge studyAm J Med68691694CrossRefPubMedGoogle Scholar
  24. 24.
    Thomas , D, Cortes, J, Giles, FJ,  et al. 2001The modified hyper-CBAD regimen in newly diagnosed adult acute lymphoblastic leukemia (ALL)Blood98590aGoogle Scholar
  25. 25.
    Cortes, J 2001Central nervous system involvement in adult acute lymphocytic leukemiaHematol Oncol Clin North Am.15145162CrossRefPubMedGoogle Scholar
  26. 26.
    Cash, J, Fehir, KM, Pollack, MS 1987Meningeal involvement in early stage chronic lymphocytic leukemiaCancer59798800PubMedGoogle Scholar
  27. 27.
    Cramer, SC, Glaspy, JA, Efird, JT, Louis, DN 1996Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological studyNeurology461925PubMedGoogle Scholar
  28. 28.
    Bower, JH, Hammack, JE, McDonnell, SK, Tefferi, A 1997The neurologic complications of B-cell chronic lymphocytic leukemiaNeurology48407412PubMedGoogle Scholar
  29. 29.
    Abrey, LE, Yahalom, J, DeAngelis,  2000Treatment for primary CNS lymphoma: the next stepJ Clin Oncol1831443150PubMedGoogle Scholar
  30. 30.
    Herrilinger, U, Schabet, M, Brugger, W, Kortmann, RD, Kuker, W,  et al. 2002German Cancer Society Neuro-Oncology Working Group NOA-03 Multicenter Trial of Single-Agent High-Dose Methotrexate for Primary CNS LymphomaAnn Neurol51247252CrossRefPubMedGoogle Scholar
  31. 31.
    Fisher, BJ, Sieferheld, W, Schultz, C, DeAngelis, L, Schold, SC, Curran, W 2001Secondary analysis of RTOG 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma with chemotherapy and hyperfractionated radiotherapyInt J Rad Oncol Biol Phy51166177CrossRefGoogle Scholar
  32. 32.
    Kantarjian, HM, Smith, T, Estey, E,  et al. 1992Prognostic significance of elevated serum beta 2-microglobulin levels in acute lymphocytic leukemiaAm J Med.93599604CrossRefPubMedGoogle Scholar
  33. 33.
    Ravandi, F, Cortes, J, Estrov, Z,  et al. 2002CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemiaLeuk Res26643649CrossRefPubMedGoogle Scholar
  34. 34.
    Mavlight, GM, Stuckey, SE, Cabanillas, FF,  et al. 1980Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determinationN Engl J Med303718722PubMedGoogle Scholar
  35. 35.
    Chamberlain, MC 1998Leptomeningeal metastases: a review of evaluation and treatmentJ Neuro Oncol3727184CrossRefGoogle Scholar
  36. 36.
    Chamberlain, M 1996

    leptomeningeal metastases

    Levin, V eds. Cancer in the Nervous SystemChurchill LivingstoneNew York282290
    Google Scholar
  37. 37.
    Wasserstrom, W, Glass, J, Posner, J 1982Diagnosis and treatment of leptomeningeal metastases from solid tumors experience with 90 patientsCancer49759772PubMedGoogle Scholar
  38. 38.
    Grossman, SA, Krabak, MJ 1999Leptomeningeal carcinomatosisCancer Treat Rev25103119CrossRefPubMedGoogle Scholar
  39. 39.
    Murray, J, Greco, F, Wolff, S,  et al. 1983Neoplastic meningitis; marked variations of cerebrospinal fluid composition in the absence of extradural blockAm J Med75289294CrossRefPubMedGoogle Scholar
  40. 40.
    Burger, B, Zimmermann, M, Mann, G,  et al. 2003Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar punctureJ Clini Oncol21184188CrossRefGoogle Scholar
  41. 41.
    Wasserstrom, WR, Schwartz, MK, Fleisher, M,  et al. 1981Cerebrospinal fluid biochemical markers in central nervous system tumors: a reviewAnn Clin Lab Sci11239251PubMedGoogle Scholar
  42. 42.
    Zanten, AP, Twijnstra, A, Hart, AA,  et al. 1986Cerebrospinal fluid lactate dehydrogenase activities in patients with central nervous system metastasesClin Chim Acta161259268CrossRefPubMedGoogle Scholar
  43. 43.
    Klee, GG, Tallman, RD, Goellner, JR,  et al. 1986Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosisMayo Clin Proc61913PubMedGoogle Scholar
  44. 44.
    Twijnstra, A, Zanten, AP, Hart, AA,  et al. 1987Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumoursJ Neurol Neurosurg Psychiatry50313320PubMedGoogle Scholar
  45. 45.
    Twijnstra, A, Ongerboer, DV, Zanten, AP,  et al. 1989Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumorsJ Neuro Oncol75763CrossRefGoogle Scholar
  46. 46.
    Stockhammer, G, Poewe, W, Burgstaller, S,  et al. 2000Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitisNeurology5416701676PubMedGoogle Scholar
  47. 47.
    Chamberlain, MC 1998Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markersNeurology5011731175PubMedGoogle Scholar
  48. 48.
    Garson, JA, Coakham, HB, Kemshead, JT,  et al. 1985The role of monoclonal antibodies in brain tumour diagnosis and cerebrospinal fluid (CSF) cytologyJ Neuro Oncol3165171Google Scholar
  49. 49.
    Hovestadt, A, Henzen-Logmans, SC, Vecht, CJ 1990Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitisBr J Cancer62653654PubMedGoogle Scholar
  50. 50.
    Boogerd, W, Vroom, TM, Heerde, P,  et al. 1988CSF cytology versus immunocytochemistry in meningeal carcinomatosisJ Neurol Neurosurg Psychiatry51142145PubMedGoogle Scholar
  51. 51.
    Kersten, MJ, Evers, LM, Dellemijn, PL,  et al. 1996Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignanciesBlood8719851999PubMedGoogle Scholar
  52. 52.
    Jeffery, GM, Frampton, CM, Legge, HM, Hart, DN 1990Cerebrospinal fluid B2-microglobulin levels in meningeal involvement by malignancyPathology222023PubMedGoogle Scholar
  53. 53.
    Oostenbrugge, RJ, Hopman, AH, Ramaekers, FC,  et al. 1998In situ hybridization: a possible diagnostic aid in leptomeningeal metastasisJ Neuro Oncol38127133CrossRefGoogle Scholar
  54. 54.
    Cibas, ES, Malkin, MG, Posner, JB,  et al. 1987Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluidAm J Clin Pathol88570577PubMedGoogle Scholar
  55. 55.
    Oostenbrugge, RJ, Hopman, AH, Arends, JW,  et al. 1998The value of interphase cytogenetics in cytology for the diagnosis of leptomeningeal metastasesNeurology51906908PubMedGoogle Scholar
  56. 56.
    Rhodes, CH, Glantz, MJ, Glantz, L,  et al. 1996A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitisCancer77543548CrossRefPubMedGoogle Scholar
  57. 57.
    Rhodes, CH, Glantz, MJ, Glantz, L, Lekos, A, Sorenson, GD, Honsinger, C, Levy, NB 1996A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitisCancer77543548CrossRefPubMedGoogle Scholar
  58. 58.
    Biesterfeld, S, Bernhard, B, Bamborschke, S,  et al. 1993DNA single cell cytometry in lymphocytic pleocytosis of the cerebrospinal fluidActa Neuropathol (Berl)86428432Google Scholar
  59. 59.
    Cheng, TM, O'Neill, BP, Scheithauer, BW,  et al. 1994Chronic meningitis: the role of meningeal or cortical biopsyNeurosurgery34590595PubMedGoogle Scholar
  60. 60.
    Glass, J, Melamed, M, Chernik, N,  et al. 1979Malignant cells in cerebrospinal fluid (CSF) the meaning of a positive CSF cytologyNeurology2913691375PubMedGoogle Scholar
  61. 61.
    Chamberlain, M, Sandy, A, Press, G. 1990Leptomeningeal metastasis a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brainNeurology40435438Google Scholar
  62. 62.
    Sze, G, Soletsky, S, Bronen, R,  et al. 1989MR imaging of the cranial meninges with emphasis on contrast enhancements and meningeal carcinomatosisAJNR10965975PubMedGoogle Scholar
  63. 63.
    Collie, DA, Sellar, RJ, Steyn, JP, Cull, RE 1999The diagnostic yield of magnetic resonance imaging (MRI) of the brain and spine requested by general practitioners: comparison with hospital cliniciansBr J Gen Pract49559561PubMedGoogle Scholar
  64. 64.
    Gomori, JM, Heching, N, Siegal, T. 1998Leptomeningeal metastases: evaluation by gadolinium enhanced spinal magnetic resonance imagingJ Neuro Oncol365560CrossRefGoogle Scholar
  65. 65.
    Chamberlain, MC 1995Comparative spine imaging in leptomeningeal metastasesNeuro-Oncol23233238CrossRefGoogle Scholar
  66. 66.
    Kim, K, Ho, S, Weinberg, P,  et al. 1982Spinal leptomeningeal infiltration by systemic cancer myelographic featuresAJR139361365PubMedGoogle Scholar
  67. 67.
    Kramer, E, Rafto, S, Packer, R,  et al. 1991Comparison of myelography with CT follow-up versus gadolinium MRI for subarachnoid metastatic disease in childrenNeurology414650Google Scholar
  68. 68.
    Chamberlain, M, Corey-Bloom, J 1991Leptomeningeal metastases indium-DTPA CSF flow studiesNeurology4117651769PubMedGoogle Scholar
  69. 69.
    Chamberlain, MC, Kormanik, P 1996Prognostic significance of indium-DTPA CSF flow studiesNeurology4616741677PubMedGoogle Scholar
  70. 70.
    Paulus, JA, Bos, GM, Lowenberg, B, Bent, MJ 1998Treatment results and the prognosis in patients with localization of non-Hodgkin's-lymphoma in the central nervous systemNed Tijdschr Geneeskd14221962200PubMedGoogle Scholar
  71. 71.
    Bokstein, F, Lossos, A, Lossos, IS, Siegal, T 2002Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapyLeuk Lymphoma43587593CrossRefPubMedGoogle Scholar
  72. 72.
    Philip, T, Guglielmi, C, Hagenbeek, A, Somers, R, Lelie, H, Bron, D, Sonneveld, P, Gisselbrecht, C, Cahn, JY, Harousseau, JL,  et al. 1995Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphomaN Engl J Med33315401545CrossRefPubMedGoogle Scholar
  73. 73.
    Williams, CD, Pearce, R, Taghipour, G, Green, ES, Philip, T, Goldstone, AH 1994Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome–a report by the European Bone Marrow Transplant Lymphoma RegistryJ Clin Oncol1224152422PubMedGoogle Scholar
  74. 74.
    Alvarnas, JC, Negrin, RS, Horning, SJ, Hu, WW, Long, GD, Schriber, JR, Stockerl-Goldstein, K, Tierney, K, Wong, R, Blume, KG, Chao, NJ 2000High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphomaBiol Blood Marrow Transplant6352358PubMedGoogle Scholar
  75. 75.
    Glantz, MJ, LaFollette, S, Jaeckle, KA, Shapiro, W, Swinnen, L, Rozental, JR, Phuphanich, S, Rogers, LR, Gutheil, JC, Batchelor, T, Lyter, D, Chamberlain, M, Maria, BL, Schiffer, C, Bashir, R, Thomas, D, Cowpens, W, Howell, SB 1999Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitisJ Clin Oncol1731103116PubMedGoogle Scholar
  76. 76.
    Chamberlain, M, Dirr, L 1993Involved field radiotherapy and intra-ommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitisJ Clin Onc1119781984Google Scholar
  77. 77.
    Chamberlain, MC, Kormanik, P, Glantz, M 1998Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitisOncol Rep5521523PubMedGoogle Scholar
  78. 78.
    Yoshida, S, Morii, K, Watanabe, M, Saito, T 2000Characteristic features of malignant lymphoma with central nervous system involvementSurg Neurol53163167CrossRefPubMedGoogle Scholar
  79. 79.
    Chamberlain, MC, Kormanik, PA 1997Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastasesJ Neurosurg87694699PubMedGoogle Scholar
  80. 80.
    Chamberlain, MC, Kormanik, PA 1997Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastasesArch Neurol5413641368PubMedGoogle Scholar
  81. 81.
    Blasberg, R, Patlak, C, Fenstermacher, J 1975Intrathecal chemotherapy brain tissue profiles after ventriculo-cisternal perfusionPharm Exp Ther1957383Google Scholar
  82. 82.
    Magrath, IT, Haddy, TB, Adde, MA 1996Treatment of patients with high-grade non-Hodgkin's lymphomas and central nervous system involvement: is radiation an essential component of therapyLeuk Lymphoma2199105PubMedGoogle Scholar
  83. 83.
    Balis, F, Poplack, D 1989Central nervous system pharmacology of antileukemic drugsAmer J Pediatr Hemat/Oncol117486Google Scholar
  84. 84.
    Collins, J 1983Pharmacokinetics of intraventricular administrationJ Neuro-Oncol1283291CrossRefGoogle Scholar
  85. 85.
    Siegal, T, Lassos, A, Pfeffer, MR 1994Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapyNeurology4414631469PubMedGoogle Scholar
  86. 86.
    Boogerd, W, Hart, AAM, Sande, ,  et al. 1991Meningeal carcinomatosis breast cancerPrognostic factors and influence of treatment. Cancer6716851695Google Scholar
  87. 87.
    Giannone, L, Greco, F, Hainsworth, J 1986Combination intraventricular chemotherapy for meningeal neoplasiaJ Clin Oncol46873PubMedGoogle Scholar
  88. 88.
    Hitchens, R, Bell, D, Woods, R,  et al. 1987A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosisJ Clin Oncol516551662PubMedGoogle Scholar
  89. 89.
    Grossman, SA, Finkelstein, DM, Ruckdeschel, JC,  et al. 1993Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitisJ Clin Oncol11561569PubMedGoogle Scholar
  90. 90.
    Shapiro, W, Young, D, Mehta, B 1975Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injectionsN Engl J Med293161166PubMedGoogle Scholar
  91. 91.
    Rabkin, CS, Yellin, F 1994Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1J Natl Cancer Inst 16;8617111716Google Scholar
  92. 92.
    Cingolani, A, Gastaldi, R, Fassone, L, Pierconti, F, Giancola, ML, Martini, M, Luca, A, Ammassari, A, Mazzone, C, Pescarmona, E, Gaidano, G, Larocca, LM, Antinori, A 2000Epstein–Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomasJ Clin Oncol1833253330PubMedGoogle Scholar
  93. 93.
    Taiwo, BO 2000AIDS-related primary CNS lymphoma: a brief reviewAIDS Read10486491PubMedGoogle Scholar
  94. 94.
    DeAngelis, LM, Wong, E, Rosenblum, M, Furneaux, H 1992Epstein–Barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphomaCancer7016071611PubMedGoogle Scholar
  95. 95.
    Desai, J, Mitnick, RJ, Henry, DH, Llena, J, Sparano, JA 1999Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphomaCancer8618401847CrossRefPubMedGoogle Scholar
  96. 96.
    Chamberlain, MC, Kormanik, PA 1999AIDS-related central nervous system lymphomasJ Neuro Oncol43269276CrossRefGoogle Scholar
  97. 97.
    Raez, LE, Patel, P, Feun, L, Restrepo, A, Raub, WA,Jr., Cassileth, PA 1998Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL)Crit Rev Oncol9199208Google Scholar
  98. 98.
    Goldstein, JD, Dickson, DW, Moser, FG, Hirschfeld, AD, Freeman, K, Llena, JF, Kaplan, B, Davis, L 1991Primary central nervous system lymphoma in acquired immune deficiency syndromeA clinical and pathologic study with results of treatment with radiation. Cancer6727562765Google Scholar
  99. 99.
    Balmaceda, C, Gaynor, JJ, Sun, M, Gluck, JT, DeAngelis, LM 1995Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implicationsAnn Neurol38202209CrossRefPubMedGoogle Scholar
  100. 100.
    Chamberlain, MC 2003Neoplastic meningitis-related encephalopathy: prognostic significance. American Academy of Neurology, Honolulu, Hawaii, March 29–April 5, 2003Neurology60A17A18CrossRefGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Marc C. Chamberlain
    • 1
  • Craig Nolan
    • 2
  • Lauren E. Abrey
    • 2
  1. 1.Department of NeurologyUniversity of Southern California/Norris Comprehensive Cancer Center and HospitalLos Angeles
  2. 2.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations